Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy

International Journal of Risk and Safety in Medicine

Volumn 23, Issue 3, 2011, Pages 171-180

  Rajesh, Radhakrishnan ^a   Vidyasagar, Sudha ^b   Varma, Danturulu Muralidhar ^b   Mohiuddin, Shabaz ^a   Noorunnisa, ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

highly active antiretroviral therapy; human immunodeficiency virus; Zidovudine induced anemia

Indexed keywords

HEMOGLOBIN; STAVUDINE; ZIDOVUDINE;

ADULT; ALGORITHM; ANEMIA; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; WORLD HEALTH ORGANIZATION;

ADULT; ANEMIA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; INCIDENCE; INDIA; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STAVUDINE; ZIDOVUDINE;

EID: 80055093320     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2011-0531     Document Type: Article

References (23)

1. World Health Organization, (home page on the internet) (2008) Available at: URL: http://www.who.int/en/ (accessed 23 October 2008).
2. Averting HIV and AIDS. (home page on the internet) (2009) Available at: URL: http://www.avert.org/ (accessed 5 January 2009).
3. F. J. Palella Jr, K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhre and G. A. Satten, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, HIV Outpatient Study Investigators, N Engl J Med 338(1998), 853-860.
4. R. Detels, A. Munoz, G. McFarlane, L. A. Kingsley, J. B. Margolick and J. Giorgi, Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration, AIDS Cohort Study Investigators, JAMA 280(1998), 1497-1503.
5. R. S. Hogg, B. Yip, C. Kully, K. J. P. Craib, M. V. O'Shaughnessy and M. T. Schechter, Improved survival among HIV-infected patients after initiation of triple drug antiretroviral regimens, CMAJ 160(5) (1999), 659-665.
6. A. Arminio Monforte, A. C. Lepri, G. Rezza, P. Pezzotti, A. Antinori and A. N. Phillips, Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral näive patients, I. C. O. N. A. Study Group. Italian Cohort of Antiretroviral-Näive Patients, AIDS 14(2000), 499-507.
7. G. M. Lucas, R. E. Chaisson and R. D. Moore, Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions, Ann Intern Med 131(1999), 81-87.
8. P. S. Sullivan, D. L. Hanson, S. Y. Chu, J. L. Jones and J. W. Ward, Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIVdisease surveillance project, Blood 91(1998), 301-308.
9. R. D. Moore, J. C. Keruly and R. E. Chaisson, Anemia and survival in HIV infection, J Acquired Imnlwre Defic Sydr Hum Retrovirol 19(1998), 29-33.
10. AHFS drug information, American society of health-system pharmacists (2010), 774-784.
11. World Health Organization, Uppsala Monitoring Center. Safety monitoring of medicinal products, guidelines for setting up and running phamacovigilance center, Geneva 1996. Available at: URL: http://www.who.int/en/ (accessed 25 January 2011).
12. AIDS Clinical Trials and Group, Table of grading severity of anemia, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, 1996.
13. R. H. Meyboom, Y. A. Hekster, A. C. Egberts, F. W. Gribnau and I. R. Edwards, Causal or casual? The role of causality assessment in pharmacovigilance, Drug Saf 17(6) (1997), 374-389.
14. C. A. Naranjo, U. Busto and E. M. Sellers, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther 30(2) (1981), 239-245.
15. S. C. Hartwig, J. Siegel and P. J. Schneider, Preventability and severity assessment in reporting adverse drug reactions, Am J Hosp Pharm 49(1992), 2229-2232.
16. G. T. Schumock and J. P. Thornton, Focusing on the preventability of adverse drug reactions, Hosp Pharm 27(6) (1992), 538.
17. F. Saali, S. Wolfgang, P. Munderi, A. Reid, A. S. Walker, D. M. Gibb, et al., Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial, Antiviral Therapy 11(2006), 741-749.
18. P. R. Koduri and S. Parekh, Zidovudine-related anemia with recticulocytosis, Ann Hematol 82(3) (2003), 184-185.
19. R. Moh, C. Danel, S. Sorho, D. Sauvageot, A. Anzian, A. Minga, et al., Haematological changes in adults receiving zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire, Antiviral Therapy 10(2005), 615-624.
20. S. E. Huffam, P. Srasuebkul, J. Zhou, A. Calmy, V. Saphonn, J. M. Kaldor, et al., TREAT Asia HIV Observational Database (TAHOD), Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med 8(7) (2007), 465-471.
21. S. M. Curkendall, J. T. Richardson, M. F. Emons, A. E. Fisher and F. Everhard, Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy, HIV 8(8) (2007), 483-490.
22. M. D. B. Stephens and Introduction, In: J. Talbot, P. Waller editors, Stephens' Detection of New Adverse Drug Reactions (5th edn), West Sussex: JohnWiley & Sons, Ltd, (2004), 1-91.
23. U. Mehta, D. N. Durrheim, M. Blockman, T. Kredo, R. Gounden and K. I. Barnes, Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: Prospective observational study, Br J Clin Pharmacol 65(3) (2008), 396-406.